Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- ATHERSYS/ANGIOTECH TO EVALUATE SAFETY OF MULTISTEM IN AMI.
- Athersys, Inc. (NASDAQ:ATHX and Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI (NASDAQ:TSX: ANP ANP>), have announced that Athersys has received authorization from the U.S. Food and Drug Administration FDA to begin a Phase I clinical trial evaluating the safety of MultiStemR in the treatment of acute myocardial infarction AMI....
- Research articles 2008-02-01
- Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell United States clinical trial in acute myocardial infarction.
- Athersys, Inc. (Cleveland, OH) and Angiotech Pharmaceuticals, Inc. (Vancouver, Canada), said that Athersys has received authorization from the United States Food and Drug Administration to begin a Phase I clinical trial evaluating the safety of MultiStem in the treatment of acute myocardial infarction AMI. The companies...
- Research articles 2007-12-01
- Canadian company boosts Athersys' fight to stem cardiovascular disease.(Angiotech Pharmaceuticals Inc.)(Athersys Inc.)
- Byline: BRANDON GLENN An "immaterial'' transaction for Angiotech Pharmaceuticals Inc., a publicly traded biotech company in Canada, could turn out to be a pivotal event in the life of 11-year-old adult stem cell company Athersys Inc. of Cleveland. Angiotech's undisclosed equity...
- Research articles 2006-06-05
- Athersys, Inc. Q3 2008 Earnings Call Transcript
- Earnings Call ExcerptAthersys, Inc. ATHX Q3 2008 Earnings Call November 10, 2008 4:30 pm ET Executives Lisa Wilson - IR, In-Site Communications Gil Van Bokkelen - Chairman and CEO B.J. Lehmann - President and CFO Analysts Adam Cutler - Canaccord Adams Matt Osborne - Lazard Craig Gordon - Cowen...
- Earnings calls 2008-11-27
Additional Resources
- Athersys lands $47.5M in private equity offering.
- Athersys Inc. has surprised itself and has raised $47.5 million in a private equity offering as it continues developing biomedical technologies designed to modify genes to prevent and fight disease. The $47.5 million is nearly double the $27.6 million Athersys intended to raise in the private...
- Research articles 2000-05-08
- Athersys deal with drug giant grows; Bristol-Myers agrees to new 3-year contract.(Brief Article)
- Athersys Inc., a biopharmaceutical company in Cleveland, is expanding its relationship with Bristol-Myers Squibb Co. to provide the pharmaceutical giant with biological targets that could lead to new drugs. A new three-year agreement with Bristol- Athersys Inc., a biopharmaceutical company in Cleveland, is...
- Research articles 2002-08-05
- Carolina courting Athersys; Durham, co-founder Willard lobbying to bring biotech star south.
- Byline: JEFF STACKLIN Economic development officials in Durham, N.C., are making a pitch to get Athersys Inc., the darling of Cleveland's biotechnology community, to move all or part of its operations to North Carolina's Research Triangle. The move seems possible, considering...
- Research articles 2002-11-25
- Aurora light maker plans rare area IPO.(Technical Consumer Products Inc)(Brief Article)
- Technical Consumer Products Inc. of Aurora, a provider of energy-efficient lighting products, plans to raise $48 million in a public stock offering and to use some of the proceeds to acquire two suppliers and more than double the size of the company's headquarters. ...
- Research articles 2001-10-22
- Late News.(brief items)
- ATHERSYS STEMS GROWTH, CUTS 12 Athersys Inc. cut 12 employees, or about 10% of its total work force, earlier this month, according to two sources close to the Cleveland biopharmaceutical company. Athersys officials, including CEO Gil Van Bokkelen, ATHERSYS STEMS GROWTH, CUTS 12...
- Research articles 2003-03-17
- Biopharmaceutical Firm Thinks about Move to St. Paul, Minn., Area.
- By Jim McCartney, Saint Paul Pioneer Press, Minn. Knight Ridder/Tribune Business News Mar. 1--Athersys Inc., the fast-growing Cleveland-based biopharmaceutical firm, is considering shifting its headquarters to the St. Paul area -- a move that could mean hundreds of jobs and millions ...
- Research articles 2003-03-01
- Northeast Ohio health care providers land $8 million for stem cell research.(Inside Track: Health Care)
- The Biomedical Research and Commercialization Program of the State of Ohio's Third Frontier Program awarded Case Western Reserve University and its partners, University Hospitals of Cleveland UHC, The Cleveland Clinic and Athersys Inc., $8 million to continue clinical commercialization programs in the Center for Stem Cell...
- Research articles 2006-08-01
- CWRU a tech center finalist; Odds good of university-led plans winning part of $40M state pot.(Case Western Reserve University)
- Byline: JEFF STACKLIN Case Western Reserve University, along with collaborators at Athersys Inc., the Cleveland Clinic, University Hospitals of Cleveland and other universities and companies, is sitting pretty as the state prepares to announce who will receive shares of $40 million set aside to...
- Research articles 2003-05-19
- << Previous
- page 1 of 1
- Next >>
